Nuvation Bio Inc.

NYSE:NUVB

Biotechnology

Healthcare
$3.78 +1.03%

+$0.06 today

Market cap
$1.33B
Beta
1.56
P/E (TTM)
-12.8
EPS (TTM)
-$0.42
52W Low $1.81High $9.75

Volume 5.96M

Average 4.07M

NUVB Income Before Tax

Profit after all operating and non-operating items but before income tax.

Nuvation Bio Inc.NYSE: NUVB

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax remains negative

Q2 FY2026 income before tax was -$62.84M, compared with -$59.01M a year earlier. Trailing-twelve-month income before tax was -$149.83M.

Context

  • Income before tax amounted to 325.3% of revenue in FY2025, down 6888.4 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$62.84M or moves back toward the trailing-twelve-month quarterly average of -$37.46M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$62.84M-1264.4% QoQ
Last fiscal yearDec 2025
-$204.63M+64.0% YoY
LTMJun 2026
-$149.83M+26.2% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.5%——
1 year+64.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(204.63M) USD
Year-over-year change
+64.0%

Income Before Tax vs competitors

How NUVB compares with its peers on the latest reported figures

  • NUVB's LTM Jun 2026 income before tax of -$149.83M is the 4th highest of the 11 companies compared; the peer median is -$208.8M.
  • Its year-over-year change of +26.2% is the 3rd highest of 11, against a peer median of -16.3%.
  • Income before tax amounts to 88.2% of revenue for NUVB, versus a peer median of 544.1%.
NUVB Competitors Peer median
Income Before Tax for NUVB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$1.16B +840.9%——
AUPHAurinia Pharmaceuticals Inc.LTM Jun 2026$160.36M +156.6%—51.5%
JANXJanux Therapeutics, Inc.LTM Mar 2026-$114.48M -47.3%—529.7%
NUVBNuvation Bio Inc.LTM Jun 2026-$149.83M +26.2%—88.2%
ABCLAbCellera Biologics Inc.LTM Sep 2026-$170.81M +16.6%—251.7%
QUREuniQure N.V.LTM Mar 2026-$203.25M +5.6%—1123.3%
GPCRStructure Therapeutics Inc.LTM Jun 2026-$214.36M -20.1%——
OCULOcular Therapeutix, Inc.LTM Mar 2026-$290.5M -50.7%—558.2%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$309.11M -37.7%—275986.6%
VRDNViridian Therapeutics, Inc.LTM Jun 2026-$386.97M -12.5%—544.1%
VERAVera Therapeutics, Inc.LTM Jun 2026-$401.89M -84.1%——
Peer median (excluding NUVB) -$208.8M-16.3%—544.1%

Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0007.87M62.9M
Cost of Revenue0007.08M8.44M
Gross Profit000795K54.46M
Gross Margin———10.1%86.6%
Research & Development69.04M87.82M71.29M524.19M115.11M
Selling, General & Admin24.28M31.92M28.53M69.23M151.56M
Operating Expenses93.32M119.73M99.82M593.42M267.52M
Depreciation & Amortization184K199K222K683K1.74M
EBITDA(86.66M)(104M)(75.58M)(566.92M)(189.21M)
EBITDA Margin———-7200.7%-300.8%
Operating Income(93.32M)(119.73M)(99.82M)(592.63M)(213.06M)
Operating Margin———-7527.3%-338.7%
Interest Income2.96M7.45M24.61M27.06M21.43M
Interest Expense000341K13.68M
Other Income / Expenses6.47M15.54M24.02M24.69M8.44M
Income Before Tax(86.85M)(104.2M)(75.8M)(567.94M)(204.63M)
Pre-Tax Margin———-7213.8%-325.3%
Income Tax Expense00000
Net Income(86.85M)(104.2M)(75.8M)(567.94M)(204.63M)
Net Margin———-7213.8%-325.3%
EPS (Basic)(0.44)(0.48)(0.35)(2.11)(0.60)
EPS (Diluted)(0.44)(0.48)(0.35)(2.11)(0.60)
Weighted Avg Shares197.89M216.72M218.88M268.77M341.54M
Weighted Avg Shares (Diluted)197.89M216.72M218.88M268.77M341.54M

Nuvation Bio Inc.

NYSE:NUVB

Intrinsic Alpha fair value

Locked

Current Price

$3.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.